Cargando…
Nutrition perceptions, needs and practices among patients with plasma cell disorders
Autores principales: | Malik, Maria A., Sweeney, Nathan W., Jafri, Mohammad, Derkach, Andriy, Chmielewski, Cynthia, Adintori, Peter A., Mailankody, Sham, Korde, Neha, Tan, Carlyn R., Hassoun, Hani, Hultcrantz, Malin, Hillengass, Jens, McCann, Susan E., Iyengar, Neil, Usmani, Saad, Giralt, Sergio A., Landgren, Ola, van den Brink, Marcel R. M., Ahlstrom, Jennifer M., Lesokhin, Alexander M., D’Souza, Anita, Chimonas, Susan, Shah, Urvi A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021216/ https://www.ncbi.nlm.nih.gov/pubmed/35443718 http://dx.doi.org/10.1038/s41408-022-00666-w |
Ejemplares similares
-
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021) -
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023) -
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)